» Articles » PMID: 10559916

SKP2 is Required for Ubiquitin-mediated Degradation of the CDK Inhibitor P27

Overview
Journal Nat Cell Biol
Specialty Cell Biology
Date 1999 Nov 13
PMID 10559916
Citations 638
Authors
Affiliations
Soon will be listed here.
Abstract

Degradation of the mammalian cyclin-dependent kinase (CDK) inhibitor p27 is required for the cellular transition from quiescence to the proliferative state. The ubiquitination and subsequent degradation of p27 depend on its phosphorylation by cyclin-CDK complexes. However, the ubiquitin-protein ligase necessary for p27 ubiquitination has not been identified. Here we show that the F-box protein SKP2 specifically recognizes p27 in a phosphorylation-dependent manner that is characteristic of an F-box-protein-substrate interaction. Furthermore, both in vivo and in vitro, SKP2 is a rate-limiting component of the machinery that ubiquitinates and degrades phosphorylated p27. Thus, p27 degradation is subject to dual control by the accumulation of both SKP2 and cyclins following mitogenic stimulation.

Citing Articles

Mitoregulin Promotes Cell Cycle Progression in Non-Small Cell Lung Cancer Cells.

Stein C, Linzer C, Heer C, Witmer N, Cochran J, Spitz D Int J Mol Sci. 2025; 26(5).

PMID: 40076565 PMC: 11899852. DOI: 10.3390/ijms26051939.


A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins.

Ganesan I, Kiyokawa H Cancers (Basel). 2025; 17(4).

PMID: 40002221 PMC: 11853300. DOI: 10.3390/cancers17040626.


Distinct outcomes from targeted perturbations of the multi-subunit SCF E3 ubiquitin ligase in blocking Trp53/Rb1-null prostate tumorigenesis.

Xue Y, Zhu L, Karan S, Locker J, Branch C, Zhang J Commun Biol. 2025; 8(1):278.

PMID: 39987265 PMC: 11846996. DOI: 10.1038/s42003-025-07662-3.


Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities.

Awan A, Osman M, Khan O Cells. 2025; 14(2).

PMID: 39851497 PMC: 11763706. DOI: 10.3390/cells14020069.


SKP1-CUL1-F-box: Key molecular targets affecting disease progression.

Zeng X, Cao J, Xu J, Zhou Z, Long C, Zhou Y FASEB J. 2025; 39(2):e70326.

PMID: 39812503 PMC: 11734646. DOI: 10.1096/fj.202402816RR.